Company intelligence / Profile preview

G3 Pharmaceuticals

Lexington, MA, United States6sense.com ↗

Ownership: Private
Development stage: Preclinical

Overview

G3 Pharmaceuticals is developing novel small molecule inhibitors targeting galectin‑3, with the aim to treat cardiovascular, renal, and lung diseases. The company has partnered with Nestlé Health Science for development efforts. Clinical results have not been published yet; programs appear to be in preclinical or early clinical stages[6].

Therapeutic areas: PulmonologyCardiovascularNephrology
Modalities: Small molecules (specifically carbohydrate-based galectin-3 inhibitors)[6]
Industry: Biotech

Drug pipeline

1 asset

G3-01

Unknown

Partnerships

Nestlé Health Science[1][6]

Beyond the preview

Go deeper on G3 Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G3 Pharmaceuticals.

Explore the full profile